This federal Project Grant award for $677,998.00, awarded by the Defense Health Agency on September 1, 2024, supports research by Weill Medical College of Cornell University, a leading private research university, to target extrachromosomal DNA (ecDNA) to reverse therapy resistance in urothelial (bladder) cancer. The funding is provided through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the public. This award will enable the institution to conduct innovative scientific studies over a 3-year period, from September 1, 2024 to August 31, 2027, with the goal of developing new therapeutic approaches to address therapy-resistant urothelial cancer. As a prominent academic medical center, Weill Medical College has a strong track record of securing federal funding to advance medical research and improve patient care.
Generated 1/28/25, 7:57 AM